Pressure on pharmaceutical profit from higher drug procurement costs and labor costs for new store openings
First written in FY2026-H1. 2 of 5 entries say "Worsened", first in 2026-05-14. Latest entry: 2026-08-10.
Miahelsa Holdings moved to the "Worse" side of this theme in 2026, the same year as the typical company in this theme.
1 other company's latest entry also says "Materialised".
- 2026-08-10MaterialisedEarnings
「On the earnings front, profits declined as personnel expenses increased following wage increases for all employees, including those in indirect departments at headquarters, in addition to the effects of drug price and dispensing fee revisions in the pharmaceuticals business.」
The effects of drug price and dispensing fee revisions continued in the pharmaceuticals business, while higher personnel expenses following wage increases for all employees also contributed to the decline in earnings. - FY2026MaterialisedAnnual report
「In addition, cost of sales increased as the procurement cost of pharmaceuticals rose.」
Higher pharmaceutical procurement costs actually occurred, and the pharmaceutical business reported higher revenue but lower profit. - FY2026-H1First statedAnnual report
「In addition to higher procurement costs for pharmaceuticals, cost of sales increased because labor costs rose as the company secured pharmacists in connection with 3 new store openings.」
Higher pharmaceutical procurement costs and increased labor costs to secure pharmacists for 3 new store openings are disclosed independently for the first time as factors that drove up cost of sales and pressured pharmaceutical business profit.